In this report, we show that affinity purified human anti-delta opioid receptor (DOR) autoantibodies from IVIG are specific to DOR and possess agonistic properties displayed by their ability to dramatically decrease forskolin stimulated cAMP accumulation. Anti-DOR autoantibody also caused phosphorylation of the opioid receptor. Anti-DOR autoantibody treatment showed a significant reduction in CXCR4 gene expression as well as surface protein expression. In contrast, anti-DOR autoantibody treatment significantly upregulated CCR5 gene and protein expression. The presence of anti-DOR autoantibodies in IVIG and their potent immunomodulatory activity is further evidence to support the cross-talk between the neuroendocrine and immune systems.
Introduction
Endogenous opioid peptides and their receptors are involved in critical physiological functions such as analgesia, regulation of the autonomic nervous system and neuroendocrine activities, respiration and gastrointestinal motility (Mellon and Bayer, 1998; Tegeder and Geisslinger, 2004) . The endogenous biological activities of the opioid neuropeptide endorphins, enkephalins and dynorphin are mediated by three classes of opioid receptors named μ MOR, δ DOR and κ KOR opioid receptors that belong to the seven transmembrane G-protein coupled receptor (GPCR) superfamily (McCarthy et al., 2001; Sharp et al., 1998c; Williams et al., 2001) . In addition to their role in the modulation of the pain networks, opioids also influence certain parameters of both the innate and adaptive immune systems (House et al., 1996; Roy et al., 2006; Vallejo et al., 2004) . Apart from cells of the central and peripheral nervous systems, immune cells, particularly under stressful conditions, produce endogenous opioids such as enkaphalins locally at the site of inflammation (Bidlack, 2000; Mellon and Bayer, 1998; Shahabi et al., 2003) . The opioids elicit analgesia by acting on the peripheral sensory nerve terminals, and also exert a range of immunomodulatory effects on T cell responses (Shahabi et al., 2003 (Shahabi et al., , 2006 . Numerous studies have demonstrated the presence of opioid receptors on peripheral blood lymphocytes (Shahabi et al., 2000; Sharp et al., 2001 Sharp et al., , 1998b Shen et al., 2005) . The distribution of the opioid receptors on various types of cells such as monocytes, macrophages and lymphocytes differ, and their expression can be modulated by factors such as the cytokine microenvironment, and the stage and state of cell differentiation and activation (Peterson et al., 1998; Sharp et al., 1998c; Shen et al., 2005) . Various groups have shown that activation of the T cell through the TCR significantly upregulates both the percentage of T cells that express DOR as well as the number of DORs expressed by each T cell (Miller, 1996; Nguyen and Miller, 2002; Shahabi et al., 2000) . DOR agonists exert a range of immunomodulatory effects on T cell responses that include, but are not limited to, T cell proliferation, cytokine production, chemotaxis, thymic T cell selection, opioid mediated modulation of the release of chemokines and expression and/or functionality of chemokine receptors on leukocytes (Benard et al., 2008; Happel et al., 2008; Jaume et al., 2007; Hebert, 2008; Finley et al., 2008b; House et al., 1996) .
Apart from the expression of the opioid receptors on immune cells, another piece of evidence that supports the bi-directional network of communication between the opiate and immune system is the discovery that IgG autoantibodies directed against the human MOR are commonly present in the serum of healthy individuals (Mace et al., 1999a (Mace et al., , 2002 . These autoantibodies display an agonistic activity, demonstrated by the inhibition of forskolin stimulated cAMP accumulation. The autoantibodies bind to the first and third extracellular loops known to be involved in ligand binding and activation of the GPCR (Mace et al., 1999b (Mace et al., , 2002 (Mace et al., , 2001 Dietrich et al., 1998) . The earlier dogma of horror autotoxicus, according to which all autoantibodies were considered to contribute to autoimmune disease, has been replaced by the knowledge that the presence of a low level of circulating serum autoantibodies is, in fact, a hallmark of a healthy immune system (Quintana and Cohen, 2004; Shoenfeld and Toubi, 2005) . While the exact function of this subset of antibodies remains to be clearly Journal of Neuroimmunology 217 (2009) [65] [66] [67] [68] [69] [70] [71] [72] [73] 
